--- title: "Evofem Biosciences | 8-K: FY2026 Q1 Revenue: USD 899 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286774708.md" datetime: "2026-05-18T12:58:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286774708.md) - [en](https://longbridge.com/en/news/286774708.md) - [zh-HK](https://longbridge.com/zh-HK/news/286774708.md) --- # Evofem Biosciences | 8-K: FY2026 Q1 Revenue: USD 899 K Revenue: As of FY2026 Q1, the actual value is USD 899 K. EPS: As of FY2026 Q1, the actual value is USD -0.04. Evofem Biosciences, Inc. announced its financial results for the three months ended March 31, 2026; however, the detailed financial results, including specific revenue, operational metrics, or cash flow figures for this period, are not provided within the text of this filing. #### Outlook / Guidance Evofem Biosciences, Inc. anticipates impacts from COGS reduction initiatives, future sales trends, cost-reduction initiatives, manufacturing efficiencies, and international market expansion. The company also expects to pursue additional financing or other strategic alternatives. It acknowledges significant risks including limited cash resources, dependence on new capital for operations, potential delays in regulatory approvals, and manufacturing and supply chain challenges. ### Related Stocks - [EVFM.US](https://longbridge.com/en/quote/EVFM.US.md) ## Related News & Research - [HUB Cyber Security fields shareholder questions ahead of Sept. 8 annual meeting](https://longbridge.com/en/news/294876332.md) - [MNTN Q2 FY26 net income turns to USD 6.7 million; revenue rises 21% to USD 82.5 million](https://longbridge.com/en/news/294864701.md) - [Bogota Financial GAAP EPS of $0.06, revenue of $4.5M](https://longbridge.com/en/news/294524183.md) - [Chimera declares Q3 2026 Series A preferred dividend of $0.5 a share](https://longbridge.com/en/news/294951609.md) - [Paramount Skydance amends 8-K to correct pro forma financial statement table in Exhibit 99.3](https://longbridge.com/en/news/294873320.md)